EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial

EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial

At a recent international oncology conference, Professor Scott Tyldesley from Vancouver, Canada, delivered an oral presentation on behalf of Professor Jim Morris, sharing the 15-year long-term survival analysis of the ASCENDE-RT trial (Abstract No. 306). This study compared the long-term overall survival (OS) and prostate cancer-specific mortality (PCSM) of an external beam radiotherapy (EBRT) boost versus a low-dose-rate (LDR) brachytherapy boost in patients with localized prostate cancer. Oncology Frontier (Mediamedic) has summarized the core academic highlights to share with our readers.
Professor Wang Sanbin: Advancing Integrative Rehabilitation and Translating Cutting-Edge Therapies in Lymphoma Care

Professor Wang Sanbin: Advancing Integrative Rehabilitation and Translating Cutting-Edge Therapies in Lymphoma Care

From November 6 to 9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was grandly convened in Kunming. As one of China’s largest and most influential oncology meetings, the conference gathered many leading national and international oncology experts to explore the latest advances and future directions in cancer prevention and treatment through the lens of integrative medicine. The event provided a high-level platform for strengthening China’s cancer diagnosis and treatment system.
Professor YanminZhao: A New Management Framework for TP53 Mutations — From MRD Monitoring to Emerging Treatment Strategies | 2025 International Cell & Immunotherapy Congress

Professor YanminZhao: A New Management Framework for TP53 Mutations — From MRD Monitoring to Emerging Treatment Strategies | 2025 International Cell & Immunotherapy Congress

mmunotherapy field, enhance communication on key scientific issues, share the latest clinical advances, and foster global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), Zhejiang Immunological Society and Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou, China, and co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory.
Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Recently, the upper urinary tract reconstruction team led by Xuesong Li, Director of the Department of Urology at Peking University First Hospital, successfully performed a domestic surgical robot–assisted laparoscopic fully intracorporeal autologous kidney transplantation for a patient with complex upper urinary tract obstruction.
Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

The evolution of breast cancer diagnosis and treatment is an epic journey spanning past and present, marked by transformative breakthroughs that have profoundly reshaped patient outcomes. From January 9 to 11, 2026, the Northern China Breast Cancer Salon · Annual Progress Review was held in Beijing. One of the most highly anticipated sessions was the Annual Review of Advances in Breast Cancer Therapy, which brought together leading experts to examine and synthesize the most significant international and domestic developments of 2025. Topics ranged from surgery, pathology, and radiotherapy to molecular classification and precision treatment, highlighting studies that have reshaped clinical practice.
Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

From January 16 to 18, 2026, the Working Meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Myeloma Expert Committee and the 2026 CSCO Academic Conference on Hematologic Malignancies were held in Haikou, China. During the meeting, Professor Honghu Zhu of Beijing Chaoyang Hospital, Capital Medical University, provided a comprehensive overview of the current challenges of hematopoietic stem cell transplantation (HSCT) in acute leukemia, the evolution of transplant indications in the era of novel agents, and future optimization strategies. His insights offered important guidance for clinicians seeking to refine treatment approaches.
CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

With continuous technological iteration in CAR-T cell therapy, fourth-generation CAR-T is increasingly demonstrating substantial clinical potential. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The meeting brought together leading hematology experts from China and abroad, focusing on cutting-edge advances and national health strategy priorities, fostering in-depth academic exchange and exploration of new directions in the field.
CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome that poses significant clinical challenges due to marked patient heterogeneity, a high proportion of relapsed or refractory cases, and limited options for precision-based interventions. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The conference brought together leading hematology experts from China and abroad, focusing on cutting-edge scientific advances and national health strategy priorities, fostering in-depth academic exchange and exploration of future directions in the field.
Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) was recently successfully held in Orlando, United States. As the year’s flagship event in hematology, the meeting presented a concentrated series of groundbreaking advances in lymphoma research, offering new directions for the optimization of clinical practice.